The 2‑μm thulium laser resection of the prostate‑tangerine technique (TmLRP‑TT) has been introduced as a minimally invasive
treatment for benign prostatic hyperplasia (BPH). This study was undertaken to assess the clinical efficacy and safety of TmLRP‑TT
for the treatment of BPH patients with previously negative transrectal prostate biopsy. A prospective analysis of 51 patients with
previously negative transrectal prostate biopsy who underwent surgical treatment using TmLRP‑TT was performed from December
2011 to December 2013. Preoperative status, surgical details, and perioperative complications were recorded. The follow‑up
outcome was evaluated with subjective and objective tests at 1 and 6 months. TmLRP‑TT was successfully completed in all patients.
Mean prostate volume, operative duration, and catheterization time were 93.3 ± 37.9 ml, 69.5 ± 39.5 min, and 6.5 ± 1.3 days,
respectively. The mean International Prostate Symptom Score, quality of life score, maximum urinary flow rate, and post‑void
residual urine volume changed notably at 6‑month follow‑up (22.5 ± 6.9 vs 6.1 ± 3.2, 4.8 ± 1.3 vs 1.1 ± 0.9, 7.3 ± 4.5 vs
18.9 ± 7.1 ml s−1, and 148.7 ± 168.7 vs 28.4 ± 17.9 ml). Two (3.9%) patients required blood transfusion perioperatively, while
3 (5.9%) patients experienced transient hematuria postoperatively, and 2 (3.9%) patients received 3 days recatheterization due
to clot retention. TmLRP‑TT is a safe and effective minimally invasive technique for patients with previously negative transrectal
prostate biopsy during the 6‑month follow‑up. This promising technology may be a feasible surgical method for previously negative
transrectal prostate biopsy in the future.

Full Text | PDF |